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ORIGINAL INVESTIGATION

Investigation of Surrogate Biomarkers Associated with Macular
Pigment Status in a Group of Older Irish Adults
Grainne Scanlon, MPhil, PhD,1* John S. Butler, PhD,2 Daniel McCartney, PhD,3 Ekaterina Loskutova, PhD,1
Rose A. Kenny, MD, PhD,4,5,6 and James Loughman, PhD1,7

Downloaded from https://journals.lww.com/optvissci by BhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD3Ypodx1mzGi1ZXpSnlNYRc+5/cvrp9btx2f5gyvIp7mg= on 10/15/2020

SIGNIFICANCE: Macular pigment (MP) confers potent antioxidant and anti-inflammatory effects at the macula;
however, its optical density in the eye is not routinely measured in clinical practice.
PURPOSE: This study explored a range of surrogate biomarkers including anthropometric, clinical, and plasma
measures that may be associated with lower MP optical density (MPOD).
METHODS: Two thousand five hundred ninety-four subjects completed a full MP assessment as part of wave 1 of
The Irish Longitudinal Study of Aging. Macular pigment optical density was measured using customized heterochromatic flicker photometry. Clinical (blood pressure), plasma (lipoproteins, inflammatory markers), and anthropometric (waist, hip, height, weight) biomarkers were measured for each participant.
RESULTS: Mean (standard deviation) MPOD for the study group was 0.223 (0.161), with a range of 0 to 1.08.
One-way ANOVA revealed that MPOD was significantly lower among participants with low plasma high-density lipoprotein (HDL; P = .04), raised plasma triglyceride-to-HDL ratio (P = .003), and raised total cholesterol–to–HDL
ratio (P = .03). Subjects with an elevated waist circumference (WC) had a significantly lower MPOD (mean, 0.216
[0.159]) compared with those with an ideal WC (mean, 0.229 [0.162]; P = .03). Significant correlates of MPOD on
mixed linear model analysis included education, smoking status, and WC.
CONCLUSIONS: Higher abdominal fat is associated with lower MPOD in this representative sample of older Irish
adults. Although altered lipoprotein profiles (low HDL, raised triglyceride-to-HDL ratio, raised total cholesterol–to–
HDL ratio) may affect the transport, uptake, and stabilization of carotenoids in the retina, these plasma biomarkers
were not predictive of low MPOD after adjustment for abdominal circumference. Although WC emerged as a viable
anthropometric predictor of lower MPOD, its effect size seems to be small.
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The concept that macular pigment may have a protective role in
neurodegenerative eye conditions such as AMD, glaucoma, and diabetes is well documented.1–3 The macula is particularly important
for central high-resolution vision and blindness results when this
area is lost to disease. The carotenoids lutein, zeaxanthin, and
meso-zeaxanthin, collectively known as macular pigment, accumulate at the macula to the exclusion of all other dietary carotenoids.
Macular pigment has a unique distribution within the retina, selectively located within the fibers of Henle in the fovea and in the inner
nuclear layer of the parafovea,4 implying that macular pigment
www.optvissci.com
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plays an important role in vision and macular health and that it is
biologically relevant to the eye.5,6
The selective absorption of short-wavelength light before photoreceptor light capture means that macular pigment plays an important role in visual performance in healthy eyes.7 Concomitantly,
through its optical filtration and antioxidant properties, macular
pigment protects the retina from (photo)-oxidative damage, thereby
potentially reducing the risk of various eye diseases including
AMD8 and diabetes.9,10 Decreased macular pigment optical density seems to be a risk factor for the development of these
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diseases,11–13 and numerous studies investigating the effects of
macular pigment augmentation have also reported beneficial effects in diseased eyes.8,9 Although the etiopathogenesis of conditions such as AMD and diabetes remains a matter of debate,
there is growing consensus that oxidative damage14,15 and associated inflammation16,17 play a significant role. The macular carotenoids exhibit neuroprotective functions at the macula,2,18 and it
has been shown that lutein and zeaxanthin can affect immune responses, reduce inflammation, and have antiangiogenic properties
in the eye.2,19,20 Therefore, the density of macular pigment offers
potential as a clinical biomarker of retinal health.
Macular pigment levels can be measured in vivo, but the relevant instrumentation is not commonly available in clinical practice.
Despite some attempts, there is still limited uptake of instruments that can successfully measure macular pigment optical
density in vivo, in clinical practice.21 Other indirect techniques
for assessing macular pigment status such as dietary and plasma
analysis have limited practical application and are generally used
only in research settings. Previous investigators have examined
and identified possible predictors of macular pigment optical density
and found associations with sex,22 iris color,23 dietary intake,24–26
plasma cholesterol and lipoprotein status,25,27,28 metabolic status,12,13 overweight/obesity status,29–31 and smoking.29 Many of
these studies, however, were based on opportunistic sampling and
restricted to small sample sizes12,13,22,23,26,28,31 and younger age
groups25,30 or relied on self-reported data.29 Although one study
investigated determinants of macular pigment optical density on
a larger older cohort (n = 1698), this research was conducted on
female subjects only.24
The evidence that does exist, however, suggests that these relationships are worth exploring in more detail. Metabolic comorbidities including overweight/obesity,29,30 hypertension,29 and
dyslipidemia,25 may adversely affect macular pigment by
compromising the availability,31 transport,27 and assimilation27
of dietary carotenoids in the retina. Consequently, there is merit
in exploring the association between macular pigment optical
density and these more commonly measured clinical and biometric parameters, which might be used to identify patients at
risk of low macular pigment, so that practitioners can implement
strategies for preventative intervention. The capacity of such an
alternate biomarker that is more readily and routinely measured
(i.e., blood pressure, plasma lipoproteins, abdominal fat) to expedite the identification of patients at risk of low macular pigment could be particularly important and may be used to
counsel patients. It is important to recognize that to minimize
the risk of macular pigment depletion it is not sufficient to supplement with macular carotenoids, but rather to suggest that
these proxy biomarkers may be used to help individuals (i.e.,
older adults free of ocular pathology) to take a more holistic evaluation of their diet and lifestyle concerning macular pigment optical
density. Management guidance may be given to patients, reinforcing the need to incorporate brightly colored fruit and vegetables as
part of one's diet, as they are rich in a broad range of antioxidants
including the target carotenoids lutein and zeaxanthin. This study
was designed therefore to address some of the limitations of previous investigations by examining the predictive capacity of a range
of measured (rather than self-reported) clinical (blood pressure),
plasma (lipoproteins, inflammatory markers), and anthropometric
(abdominal fat) parameters as possible predictors of macular pigment optical density in a large representative group (n = 2594) of
older men and women.
www.optvissci.com

METHODS
Study Design and Population
Cross-sectional data from wave 1 of The Irish Longitudinal
Study on Aging were analyzed in this study, which was conducted
during the period between October 2009 and July 2011. Participants were recruited to provide a stratified clustered sample representative of the population 50 years or older living in Ireland as
described in detail elsewhere.32,33 In brief, information on health
behaviors and lifestyle patterns was captured by trained professional
interviewers in participants' own homes using computer-aided personal interview.34 Participants were then invited to take part in a
health assessment.35 Macular pigment measurement was conducted only on participants who attended a health center (Fig. 1).
The current study was approved by the Technological University
Dublin Research Ethics Committee, and all experimental procedures
adhered to the tenets of the Declaration of Helsinki. All participants
provided written informed consent before participation in the study.

FIGURE 1. Flowchart illustrating the selection of study participants
and reasons for exclusion from the original participant group.
MPOD = macular pigment optical density; TILDA = The Irish Longitudinal Study on Aging; VA = visual acuity.

Optom Vis Sci 2020; Vol 00(00)

Copyright © American Academy of Optometry. Unauthorized reproduction of this article is prohibited.

2

Biomarkers for Lower Macular Pigment — Scanlon et al.

Demographic, Health, and Lifestyle Factors
Demographic and lifestyle factors were captured for the study
group. The presence or absence of hypertension was also examined. Participants were defined as hypertensive if mean seated systolic blood pressure exceeded 140 mmHg or mean seated diastolic
blood pressure exceeded 90 mmHg.

Macular Pigment Optical Density Assessment
Macular pigment optical density was measured by customized
heterochromatic flicker photometry using the Macular Metrics
Densitometer (Macular Metrics, Rehoboth, MA). This device was
modified specifically for The Irish longitudinal Study on Aging,
and the method of measurement has been described in detail elsewhere.36 In brief, macular pigment optical density was measured
centrally at 0.5° (i.e., 1° stimulus) and peripherally at 7° (parafoveal
target at 7°). Macular pigment assessment was carried out on the
eye with the best visual acuity, or if there was equal vision in both
eyes, the right eye was chosen.36 Corrected visual acuity was measured using the Early Treatment Diabetic Retinopathy Study
LogMAR chart at a distance of 4 m using participants' existing prescription where necessary. Participants with a visual acuity worse
than 0.5 LogMAR were excluded from the analysis (Fig. 1).

Anthropometric Assessment
Height (in centimeters) and weight (in kilograms) were measured to one decimal place using a Seca wall–mounted measuring
rod and Seca electronic floor scales, as described in detail elsewhere.34 Body mass index was calculated from measured height
and weight as weight (in kilograms)/height (in meter squared), with
obesity classified as a body mass index >30 kg/m2.37 Waist and hip
circumferences were measured to the nearest centimeter. Ideal
waist circumference was defined as a waist circumference of ≤88
cm in women and ≤102 cm in men, whereas central obesity was
defined as a waist circumference >88 cm in women and >102
cm in men. Waist-to-height ratio and waist-to-hip ratio were calculated based on measured data. Cutoff thresholds for ideal and excess waist-to-height ratio were taken as less than or greater than
0.53 in women and 0.57 in men, respectively. For waist-to-hip ratio, cutoff thresholds of less than or greater than 0.85 in women
and less than or greater than 1.00 in men defined ideal and elevated waist-to-hip ratios.38,39

Plasma Analysis
A blood sample was provided for plasma analysis using defined
phlebotomy protocols, which are described in detail elsewhere.34,35
Respondents were not asked to fast before the health assessment,
and plasma was analyzed for a complete lipid profile, including
total cholesterol, high-density lipoprotein, low-density lipoprotein,
and triglycerides, each measured in millimoles per liter. Triglyceride–
to–high-density lipoprotein ratio, total cholesterol–to–high-density
lipoprotein ratio, and non–high-density lipoprotein cholesterol (total
cholesterol minus high-density lipoprotein) were calculated from
measured data. Cutoffs were applied to indicate high/low or ideal
plasma lipid levels as per 2016 European Society of Cardiology/
European Atherosclerosis Society guidelines (Table 2).40 Plasma vitamin D levels (25-hydroxyvitamin D; in nanomoles per liter) were
also measured, and participants were considered vitamin D deficient
if plasma levels were ≤50 nmol/L and sufficient if plasma levels were
>50 nmol/L as per Institute of Medicine vitamin D guidelines.41 Inflammatory marker C-reactive protein (in micrograms per liter) and
www.optvissci.com

glycated hemoglobin (in percent) were also measured. Threshold
values of >3.00 μg/L for high and ≤3.00 μg/L for ideal were used
for plasma C-reactive protein,42 and cutoff values of ≤5.00% and
>5.00% were used for glycated hemoglobin.

Statistical Analysis
The statistical software package SPSS for Microsoft Windows (v.
25.0; IBM Corp., Armonk, NY) was used for analysis. To account for the
fact that the study response rate varied between different subgroups of
the population, inverse probability weights were calculated for the main
sample (computer-assisted personal interview participants) using the
Quarterly National Household Survey (2010). The probability of participation in the health center also varied according to health, education,
age, and smoking; therefore, a specific “health center weight” was created. A detailed description of the weighting procedures used in The
Irish Longitudinal Study on Aging is given elsewhere.43
Demographic data for eligible study participants were compared
with those of the overall health center population using χ2 analyses, to explore if they differed from the representative sample. Data
for the study group were tested for normality using the
Kolmogorov-Smirnov test. One-way ANOVA was used to test differences in means for normally distributed parameters. For categorical data, cross-tabulation with χ2 analysis was used. Pearson
product-moment correlation tests were performed to assess the relationship between normalized macular pigment optical density
and other study variables, where appropriate. A mixed linear model
analysis (fixed effect) was carried out to estimate the independent
association between putative predictor variables (behavioral, clinical, anthropometric, and plasma biomarker parameters) and normalized macular pigment optical density. Data are presented as
mean (standard deviation) throughout. The level of statistical significance was set at P < .05 for all analyses.

RESULTS
In total, 8175 individuals 50 years or older participated in the
study. Of these, 5275 consented to and participated in the health
center–based assessment as part of wave 1 of The Irish Longitudinal
Study on Aging. For various reasons, 2681 participants were excluded
from the current analysis, leaving an overall study population of 2594
(Fig. 1). The main reasons for exclusion related to unsuccessful
macular pigment optical density measurement or the presence
of retinal pathology. Participants were identified as having
AMD, cataracts, and glaucoma from the computer-assisted personal interview. The presence or absence of diabetes was identified from prescribed diabetes medications at the time of the
interview (identified using the Anatomic Therapeutic Classification codes “A10A” for insulin and “A10B” for oral hypoglycemic
medications), from the computer-assisted personal interview,
and/or from measured glycated hemoglobin (glycated hemoglobin, >6.4% [diabetes] and 5.7 to 6.4% [pre-diabetes]), as per
American Diabetes Association cutoff values.44
A χ2 test of independence was performed to examine the relationship between the center population (n = 5275) and participants with a valid macular pigment optical density assessment
(n = 2594). The age profile of study participants (mean age, 62.0
[8.5] years; range, 50 to 93 years) was similar to the overall health
center–assessed population (mean age, 61.4 [7.6] years; range, 51
to 86 years), and there was no significant difference in sex or education status between the two groups (P = .88 and P = .77, respectively).
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The distribution of macular pigment optical density was
skewed; therefore, a square root transformation of the macular pigment optical density data was performed. The derived data were normally distributed and used as the dependent variable for subsequent
statistical analyses of macular pigment optical density. For ease of
interpretation, mean and standard deviation of macular pigment optical density data are presented as the nontransformed original measure for participants. Mean (standard deviation) macular pigment
optical density for the study group was 0.223 (0.161), with a range
of 0 to 1.08. Differences in normalized macular pigment optical
density by demographic (age group, sex, education status), health,
and lifestyle variables (smoking, hypertension, physical activity,
and cataracts) were examined. Our findings concur with previously
reported statistically significant associations between sex, educational status, and smoking with macular pigment optical density
in The Irish Longitudinal Study on Aging data set (P < .05 for all), despite a slightly different study sample (participants with AMD, glaucoma, diabetes, and pre-diabetes were excluded from the current
analysis of healthy individuals but not in a previous study).29

Clinical, Anthropometric, and Biomarker Associations
with MPOD
Clinical Factors
We found no correlation between measured hypertension status
(with or without treatment) and macular pigment optical density in
the current study (n = 2591; t = 1.105; P = .33).

Anthropometric Factors
Macular pigment optical density was significantly and negatively correlated with all anthropometric measures (body mass index, waist circumference, waist-to-height ratio, waist-to-hip ratio)
on univariate analysis (Pearson r = −0.047, −0.073, −0.060,

and −0.081, respectively; P < .05 for all). Waist circumference,
however, emerged as the only anthropometric variable associated
with lower macular pigment optical density on binary univariate
analysis. Participants with an elevated waist circumference had a
significantly lower macular pigment optical density (mean, 0.216
[0.159]) compared with participants with ideal waist circumference
(mean, 0.229 [0.162]; n = 2589; t = 2.119; P = .03; Table 1, Fig. 2).
The violin plots in Fig. 2 show similar distribution density plots and interquartile ranges for participants with excess and ideal waist circumference. Although the mean macular pigment optical density was
significantly lower among subjects with a higher waist circumference,
the differences were subtle and not clinically meaningful (value,
0.013 optical density units), as illustrated in Fig. 2. Macular pigment
optical density did not differ significantly according to any other anthropometric measures (P > .05 for all; Table 1).

Plasma Biomarkers
Participants with ideal plasma levels of high-density lipoprotein
had a significantly higher macular pigment optical density than did
those with low high-density lipoprotein levels (n = 2587;
t = −2.077; P = .04; Table 2, Fig. 3A). Macular pigment optical
density was also significantly lower among participants with a
raised triglyceride–to–high-density lipoprotein ratio (n = 2587;
t = 2.994, P = .003; Table 2, Fig. 3B) and among participants with
a raised total cholesterol–to–high-density lipoprotein ratio
(n = 2574; t = 2.166; P = .03; Table 2, Fig. 3C). The violin plots
in Fig. 3 show similar distribution plots and interquartile ranges
for each of the three groups. The magnitude of all statistically significant differences (0.011, 0.019, and 0.015 optical density
units, respectively) was not, however, clinically important, as illustrated in Fig. 3. One-way ANOVA revealed no significant difference
in macular pigment optical density levels for any other plasma biomarkers (P > .05 for all; Table 2).

TABLE 1. MPOD according to anthropometric biomarkers in the study population (normalized MPOD)
Variable

n

Mean (SD) MPOD

25th

50th

75th

P sig.

.83

Anthropometric biomarkers
BMI (kg/m2)
Ideal (≤30)

1387

0.223 (0.161)

0.100

0.191

0.310

Excess (>30)

1203

0.223 (0.160)

0.101

0.195

0.316

WC (cm)
Ideal (≤102 M, ≤88 F)

1433

0.229 (0.162)

0.105

0.196

0.319

Excess (>102 M, >88 F)

1158

0.216 (0.159)

0.096

0.187

0.301

1637

0.225 (0.158)

0.105

0.195

0.314

954

0.219 (0.165)

0.093

0.189

0.307

.03*

WHpR
Ideal (≤1.00 M, ≤0.85 F)
Excess (>1.00 M, >0.85 F)

.13

WHtR
Ideal (≤0.57 M, ≤0.53 F)

1307

0.228 (0.161)

0.107

0.197

0.317

Excess (>0.57 M, >0.53 F)

1282

0.219 (0.162)

0.095

0.188

0.306

.08

ANOVA was used to check for MPOD differences among anthropometric and physical biomarkers. P values are reported using MPOD square root transformation (normalized MPOD) and reflect the probability associated with the given F statistic. The following cutoffs were applied to indicate ideal or excess
obesity measures for the following variables: BMI (ideal, ≤30; excess, >30 kg/m2, WC (ideal, ≤88 cm F and ≤102 cm M; excess, >88 cm F and >102 cm M),
WHtR (ideal, ≤0.53 F and ≤0.57 M; excess, >0.53 F and >0.57 M), and WHpR (ideal ≤0.85 F and ≤1.00 M; excess, >0.85 F and >1.00 M37–39). *Significant at the .05 level. BMI = body mass index; F = female; M = male; MPOD = macular pigment optical density; SD = standard deviation; sig. =
significance; WC = waist circumference; WHpR = waist-to-hip ratio; WHtR = waist-to-height ratio.
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FIGURE 2. Violin plot of MPOD distribution according to waist circumference status, illustrating the substantially lower MP levels among
subjects with a higher waist circumference (ANOVA). MP = macular
pigment; MPOD = macular pigment optical density.

Mixed Linear Model Effects
A mixed linear model analysis was carried out on normalized
macular pigment optical density versus demographic, behavioral,
anthropometric, and plasma biomarker as independent variables.
Low education, current smoking, and elevated waist circumference
were significant predictors of macular pigment optical density in
this regression model (Table 3). None of the plasma biomarkers
(high-density lipoprotein, triglyceride–to–high-density lipoprotein
ratio, total cholesterol–to–high-density lipoprotein ratio, vitamin
D, C-reactive protein, or glycated hemoglobin) were significantly
associated with macular pigment optical density in this model
(P > .05 for all variables; Table 3).

DISCUSSION
The key finding to emerge from this study is the observation that
participants with increased central adiposity, as indicated by an elevated waist circumference, had a significantly lower macular pigment optical density compared with those with ideal measures.
Macular pigment was also lower among participants with an altered
lipoprotein profile, that is, in participants with raised plasma
triglyceride–to–high-density lipoprotein ratio, raised plasma total
cholesterol–to–high-density lipoprotein ratio, and low plasma
high-density lipoprotein. In addition, male sex, current smoking,
and low education status were associated with lower macular pigment optical density, findings that concur with previously reported
analyses on a similar cohort.29 Elevated waist circumference, current smoking, and low educational attainment persisted as predictors of low macular pigment optical density on mixed linear model
analysis, after adjusting for all other covariates.
Consistent with most previous reports,24,29,31 macular pigment
optical density was, in fact, significantly and negatively associated
www.optvissci.com

with all measures of overweight/obesity, including body mass index, waist circumference, waist-to-height ratio, waist-to-hip ratio
(Pearson r; P < .05 for all). With cutoff levels applied to classify participants into binary categories (obese or nonobese),38 elevated
waist circumference emerged as the main anthropometric variable
associated with lower levels of macular pigment optical density.
Carotenoids, such as lutein and zeaxanthin, are known to accumulate in adipose tissue, and in visceral fat in particular31,45; therefore, distribution of body fat is an important consideration.46
Higher waist circumference has previously been reported to be
the strongest nondietary predictor of low macular pigment optical
density,24 and findings from the Third National Health and Nutrition Examination Survey revealed that participants with higher
waist circumference values were increasingly likely to have hypertension, diabetes, dyslipidemia, and the metabolic syndrome,47
metabolic correlates independently associated with lower macular
pigment optical density.12,13,27
As an indicator of “abdominal” obesity,24,47 waist circumference is receiving increased attention as a more clinically relevant measure of adiposity compared with body mass index.
Intra-abdominal fat may have different metabolic consequences
compared with other patterns of fat distribution or overall adiposity, as it is more biologically active. Intra-abdominal fat is
associated with inflammation due to the increased production
of adipocytokines.48 The associated inflammation becomes
chronic; therefore, obesity is now considered a low-grade inflammatory condition, which in turn leads to an increase in oxidative stress.49 Chronic inflammation and associated oxidative
stress exert a greater demand on antioxidant defenses within
the body, defenses that tend to be lower in obese individuals50
and in older adults.51 Sex differences also exist in relation to how
body fat is deposited,52 and there is evidence for sex-related differences in the accumulation of carotenoids.53,54 Interestingly, we
found that macular pigment optical density was 9% lower in men
compared with women (P = .004), possibly explained by the fact
that men store more fat in the visceral (abdominal) fat depot,52
thereby making these pigments less available to retinal tissue.55,56
Thus, lower antioxidant activity may relate not only to lower intake
of antioxidants and phytochemical rich foods in older adults (e.g.,
fruits, vegetables, and legumes)57 and reduced activity of endogenous antioxidative enzymes,50,51 but also to decreased availability52
and increased utilization of these molecules. Collectively, these
factors may lead to antioxidant depletion, including lower levels
of macular pigment in the eye.2,14
Another interesting finding is the observation that macular pigment optical density was significantly lower in participants with
raised plasma triglyceride–to–high-density lipoprotein ratio (>0.87
mmol/L) and in those with raised plasma total cholesterol–to–highdensity lipoprotein ratio (>3.5 mmol/L). Although these relationships
did not persist on mixed linear model analysis, the lower macular
pigment optical density levels observed among participants with
low plasma high-density lipoprotein corroborate previous findings
that identified an association between plasma high-density lipoprotein and macular pigment optical density.58 Dyslipidemia is
often characterized by low levels of high-density lipoprotein,
raised triglycerides, and smaller, more atherogenic low-density lipoprotein particles.59 Because carotenoids are bound to circulating lipoproteins, the relation between plasma levels of the various
lipoproteins and macular pigment optical density is of interest.
Evidence suggests that high-density lipoprotein is a major carrier
of lutein to the eye.27 Furthermore, high-density lipoprotein is a
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TABLE 2. MPOD according to plasma biomarkers in a normal population (normalized MPOD)
Variable

n

Mean (SD) MPOD

25th

50th

75th

Ideal ≤5.00

1040

0.224 (0.161)

0.109

0.192

0.315

High >5.00

1549

0.222 (0.160)

0.096

0.192

0.312

Ideal >1.6

1126

0.229 (0.160)

0.104

0.203

0.323

Low ≤1.6

1463

0.218 (0.161)

0.096

0.183

0.305

Ideal ≤2.6

833

0.222 (0.157)

0.109

0.190

0.314

High >2.6

1756

0.223 (0.162)

0.098

0.193

0.312

Ideal ≤1.7

1628

0.224 (0.161)

0.102

0.192

0.313

High >1.7

961

0.220 (0.161)

0.097

0.191

0.312

Ideal ≤3.4

1044

0.224 (0.159)

0.108

0.190

0.314

High >3.4

1541

0.222 (0.162)

0.098

0.194

0.311

Ideal ≤0.87

1187

0.233 (0.163)

0.106

0.204

0.322

High >0.87

1402

0.214 (0.158)

0.095

0.182

0.304

P

Plasma biomarkers
TC (mmol/L)
.74

HDL (mmol/L)
.04*

LDL (mmol/L)
.97

TG (mmol/L)
.49

Non-HDL (mmol/L)
.72

TG/HDL-C ratio
.003*

TC/HDL-C ratio
Ideal ≤3.5

1483

0.229 (0.164)

0.105

0.200

0.319

High >3.5

1093

0.214 (0.156)

0.096

0.180

0.300

963

0.223 (0.159)

0.107

0.191

0.305

1609

0.222 (0.162)

0.096

0.192

0.314

Low ≤3.0

1927

0.224 (0.158)

0.103

0.196

0.314

High >3.0

644

0.218 (0.170)

0.093

0.181

0.305

≤5.00

1206

0.221 (0.159)

0.101

0.188

0.309

>5.00

1388

0.225 (0.162)

0.101

0.196

0.316

.03*

Vitamin D (nmol/L)
Low ≤50
Optimal >50

.65

CRP (μg/L)
.19

HbA1c (%)
.63

ANOVA was used to check for normalized MPOD differences among plasma biomarkers. P values are reported using MPOD square root transformation
(normalized MPOD) and reflect the probability associated with the given F statistic. The following cutoffs were applied to plasma levels: HDL (high risk,
≤1.6 mmol/L; low risk, >1.6 mmol/L), LDL (high risk, >2.6 mmol/L; low risk, ≤2.6 mmol/L), TC (high risk, >5.00 mmol/L; low risk, ≤5.00 mmol/L), TG
(high risk, >1.7 mmol/L; low risk, ≤1.7 mmol/L), TG/HDL-C ratio (high risk, >0.87 mmol/L; low risk, ≤0.87 mmol/L), TC/HDL-C ratio (high risk, >3.5
mmol/L; low risk, ≤3.5 mmol/L), non-HDL (high risk, >3.4 mmol/L; low risk, ≤3.4 mmol/L) as per 2016 European Society of Cardiology/European Atherosclerosis Society guidelines,40 plasma vitamin D (25-hydroxyvitamin D) levels (deficient, ≤50 nmol/L; sufficient, >50 nmol/L) as per Institute of Medicine vitamin D guidelines,41 plasma CRP levels (high risk, >3.00 mg/L; low risk, ≤3.00 μg/L),35 and HbA1c (high, >5.00%; ideal, ≤5.00% (42.1 mmol/
mol) as per American Diabetes Association guidelines.42 *Significant at the .05 level. CRP = C-reactive protein; HbA1c = glycated hemoglobin; HDL =
high-density lipoprotein; LDL = low-density lipoprotein; MPOD = macular pigment optical density; non-HDL = total cholesterol minus high-density lipoprotein; SD = standard deviation; sig. = significance; TC = total cholesterol; TC/HDL-C = total cholesterol–to–high-density lipoprotein cholesterol ratio;
TG = triglyceride; TG/HDL-C = triglyceride to high-density lipoprotein cholesterol ratio.

known ligand for scavenger receptor class B type 1, and the mechanism of xanthophyll uptake in the retina seems to be entirely scavenger receptor class B type 1 dependent.56
Vitamin D deficiency has repeatedly been associated with ocular disease.60,61 Of interest, we recently reported that individuals
with type 2 diabetes who were vitamin D deficient (≤50 nmol/L)
had a significantly lower macular pigment optical density and that
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vitamin D was a significant positive predictor of macular pigment
optical density on multivariate analysis in this study group.62 This
study, however, suggests that the association between vitamin D
status and macular pigment optical density does not persist among
older adults who are free of ocular pathology. Furthermore, no relationship was observed between macular pigment optical density
and the inflammatory marker C-reactive protein.
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FIGURE 3. Violin plots of MPOD differences illustrating the following:
lower MPOD among subjects with low HDL (A), lower MPOD among
subjects with raised TG/HDL ratio (B), and lower MPOD among subjects with raised TC/HDL ratio (C; ANOVA). HDL = high-density lipoprotein; MPOD = macular pigment optical density; TC/HDL = total
cholesterol–to–high-density lipoprotein ratio; TG/HDL = triglyceride–
to–high-density lipoprotein ratio.
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This population-based representative study advances previously
published work that also used The Irish Longitudinal Study on Aging data to explore macular pigment optical density,29 as the analyses herein relied much less on self-reported data. A large number
of subjects were excluded from the overall macular pigment analysis (n = 2014), and possible reasons for this included the following:
technical issues, poor fixation, and poor visual acuity, among
others. Although customized heterochromatic flicker photometry
is one of the most common methods of measuring macular pigment, it is challenging to perform, particularly so for older adults.36
Research has shown that some participants have difficulty performing this technique, with dropout rates varying from 10 to
20%.36,63 A χ2 test of independence was performed, however,
comparing the center population (n = 5275) and the smaller
sample of participants with a valid macular pigment optical density assessment (n = 2594), and this test confirmed that there
was no significant difference in age, sex, or education status between the two groups. More importantly the attenuated number
of participants in the current study did not seem to have an impact on the validity of our findings as we confirmed previously reported analyses on a similar cohort.29 Despite differences in
inclusion criteria, the relationship between education and
smoking status and macular pigment optical density observed
therein and elsewhere was confirmed in our analysis.24,29 Some
discrepancies did emerge, however. Self-reported measures of
high cholesterol, for example, were not associated with macular
pigment optical density according to the previous analysis,29
whereas the analysis of direct cholesterol measures taken herein
suggests that dyslipidemia (i.e., low plasma high-density lipoprotein, raised triglyceride–to–high-density lipoprotein ratio, raised
total to high-density lipoprotein ratio) may have implications for the
delivery and uptake of macular pigment in the eye. In addition, although an inverse association between self-reported high blood
pressure and macular pigment was also previously reported,29 we
found no association between measured hypertension (treated or
untreated) and macular pigment optical density on either univariate or mixed linear model analysis. These direct measurements
(systolic and diastolic, in millimeters of mercury) would seem
to outweigh self-reported data.29 Interestingly, we recently reported that individuals with diabetes and hypertension had a
significantly lower macular pigment optical density compared
with those without,62 which suggests that when conditions coexist the redox balance may become increasingly upset, and that
oxidative stress may increase considerably in hypertension, especially as a diabetic comorbidity.64 Hypertension, however,
does not seem to affect or deplete macular pigment, in older
adults, who are free of ocular pathology.
A number of variables did not persist as predictors of macular
pigment optical density on mixed linear analysis (i.e., sex and plasma
lipoproteins) despite significant outcomes on univariate analysis. It is
possible that these variables have some underlying associations with
other variables. Therefore, when these variables are included in the
model, the variance of one is accounted for by the others, and hence,
it is no longer significant. Although sex (male) and lipoprotein (low
high-density lipoprotein, raised triglyceride to high-density lipoprotein,
raised total to high-density lipoprotein ratio) status contribute to lower
levels of macular pigment, it seems that waist circumference status is
a more robust predictor of low macular pigment optical density. It is
important to note, however, that the small difference in mean macular
pigment optical density between participants with and without elevated waist circumference suggests that any effect size is likely to
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TABLE 3. Mixed linear model effects: relationship between demographic, behavioral, anthropometric, and plasma biomarkers and MPOD
Parameter

Estimate

Std. error

T

(Normalized) MPOD P

Intercept

0.448

0.085

5.297

<.0001

Sex* (female)

0.011

0.008

1.284

.20

Secondary

0.023

0.010

2.376

.02

Tertiary/higher

0.038

0.010

3.866

<.0001

Past

−0.004

0.008

−0.588

.56

Current

−0.022

0.011

−2.011

.04

−0.001

0.000

−2.415

.02

0.006

0.013

0.454

.65

−0.000

0.000

−0.728

.47

0.000

0.000

0.745

.46

Education

Smoking†

WC
HbA1c
Vitamin D
CRP‡ (>3 μg/L)
HDL

−0.009

0.012

−0.781

.44

TG/HDL ratio

−0.001

0.005

−0.161

.87

TC/HDL ratio

−0.001

0.005

−0.145

.89

Hypertension§
Hypertensive

0.008

0.007

1.056

.29

Hypertensive (not medicated)

0.002

0.010

0.188

.85

0.018

0.014

1.291

.20

Cataracts (no)

Dependent variable: MPOD square root transformation (normalized MPOD). Continuous variables: WC, HbA1c, vitamin D, HDL, TG/HDL ratio, and TC/
HDL ratio. Bold values indicates significant at the .05 level. *Male (reference group). †Never smoked (reference group). ‡CRP (≤3 mg/L; reference
group). §No hypertension (reference group); Yes cataracts (reference group). CRP = C-reactive protein; HbA1c = glycated hemoglobin; HDL =
high-density lipoprotein; MPOD = macular pigment optical density; Std. error = standard error; TC/HDL = total cholesterol–to–high-density lipoprotein
ratio; TG/HDL = triglyceride–to–high-density lipoprotein ratio; WC = waist circumference.

be modest and not particularly useful in terms of predictive capacity
from a clinical perspective.
Macular pigment was measured using customized heterochromatic flicker photometry, a technique that has been validated in
older subjects63,65 and found to be reliable.63 Macular pigment
measurements have, however, shown a degree of variability across
studies.24,65–67 For example, Stringham et al.65 measured the
density of macular pigment in patients with intermediate AMD
using a similar device and retinal eccentricity (0.5°), and the mean
optical density was 0.37 (0.24). Subjects in the Carotenoids in
Age-Related Eye Disease Study had average macular pigment
levels of 0.36 (0.22) for the right eye and 0.34 (0.21) for the left
eye, and these participants were of similar age.24 We acknowledge
that the mean macular pigment optical density in the current study
was notably lower than previously reported.24,65 Our findings suggest that older Irish adults have lower macular pigment levels on
average. It is worth noting that the prevalence of conditions that
might affect macular pigment optical density levels is relatively
high in Ireland, including AMD,68 glaucoma,69 and type 2 diabetes.70 The lower levels of macular pigment observed in the current
study may therefore reflect the combined influence of inadequate
dietary intake and increased utilization of these phytonutrients.51
Given the variety of mechanisms that may contribute to macular
pigment depletion and the ocular risks associated with such depletion in this age group, the importance of diet cannot be
overemphasized. The provision of colored fruit and vegetables,
which are rich in a broad range of antioxidants including the target
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carotenoids lutein and zeaxanthin, and/or supplementation with
these nutrients represent an obvious recommendation, given the
putative protection that this pigment confers against age-related
vision loss. These recommendations should now be subject to
further research. Limitations of the current study include the
failure to assess dietary intake or plasma levels of the carotenoids lutein and zeaxanthin, as macular pigment optical density
is influenced by both intake and individual efficacy of absorption.71 It is also worth noting that the high variability and lower
levels of macular pigment optical density levels across different
people may also be subject to genetic variation,72 a factor that is
not accounted for in our analysis. Information on supplement
usage was also not assessed, which would have added to the interpretation of our findings, particularly those in relation to vitamin D and macular pigment optical density. Despite these
drawbacks, the representative study design, the unique sampling
method (which includes both male and female subjects), the use
of measured rather than self-reported biomarkers,29 and the detailed exclusion criteria, we believe that our findings and the conclusions drawn from our findings concerning macular pigment
optical density are representative of the older Irish population.
In conclusion, we report that elevated waist circumference and
dyslipidemia may have important implications for the storage, delivery,
and uptake of lutein and zeaxanthin in the eye. Determinants of macular pigment optical density (i.e., education status, tobacco use, waist
circumference) remain statistically significant after mixed linear model
analysis. Although no strong predictor of macular pigment optical
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density status emerged in this analysis, the capacity of more commonly
measured surrogate biomarkers to help identify people at risk of low
macular pigment merits further consideration. Given the marginal

statistical significance of many of our findings, further research is
necessary to refine our understanding of the observed relationships,
as macular pigment is not routinely measured in clinical practice.
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